Skip to content
Review Open access

Evolving pharmacotherapy in Alzheimer’s disease: from symptomatic management to disease modification-A PRISMA 2020-guided narrative review

Aug 2026 · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · Vol 62 · 0 citations · 93 references

TL;DR

Overall, symptomatic therapies continue to represent the foundation of AD management, whereas anti-amyloid monoclonal antibodies mark an important, although incremental, transition toward disease modification in carefully selected patients.

Abstract

Alzheimer’s disease (AD) is the leading cause of dementia worldwide and poses an increasing challenge for ageing populations. For decades, pharmacologic management has relied on cholinesterase inhibitors and memantine, which provide modest symptomatic benefit without altering the underlying neurodegenerative process. Recent advances in anti-amyloid monoclonal antibodies and investigational therapies targeting tau pathology, neuroinflammation, and metabolic dysfunction have renewed interest in disease-modifying therapies. This PRISMA 2020-guided narrative review critically evaluates current and emerging pharmacotherapies for AD, with emphasis on clinical efficacy, safety, and relevance to geriatric practice. A structured search of PubMed/MEDLINE, Embase, Scopus, Web of Science, CENTRAL, and ClinicalTrials.gov identified 71,663 records published between January 2000 and January 2026. After screening and eligibility assessment, 18 randomized and phase II/III clinical trials were included in the qualitative synthesis. Owing to substantial heterogeneity in study design, patient populations, and outcome measures, findings were synthesized narratively rather than quantitatively. Cholinesterase inhibitors and memantine were associated with small-to-moderate improvements or stabilization in cognition and global function, although limited durability and tolerability may restrict long-term use. Anti-amyloid monoclonal antibodies, particularly lecanemab and donanemab, demonstrated statistically significant slowing of cognitive decline in early AD; however, the absolute clinical benefits remained modest and were accompanied by amyloid-related imaging abnormalities, necessitating careful monitoring with magnetic resonance imaging. Emerging therapies targeting tau pathology, neuroinflammatory pathways, and metabolic dysfunction remain investigational. Overall, symptomatic therapies continue to represent the foundation of AD management, whereas anti-amyloid monoclonal antibodies mark an important, although incremental, transition toward disease modification in carefully selected patients.

Read PDF

Similar papers

Review Open access Sep 2026

Understanding Alzheimer's disease through biomarkers: pathology, progression, and clinical application.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide accounting for an estimated 60% to 80% of cases. Biomarkers play an integral role in AD randomized clinical trials (RCTs), providing objective measures of disease pathology, progression, and therapeutic effi...

Xiao-Lan Zhang, Michael F. Murphy, Henry J. Riordan et al. · 0 citations
Review Open access 2026

Immunotherapeutic Strategies Targeting Amyloid-β and Tau in Alzheimer’s Disease: A Systematic Review of Clinical Efficacy, Safety, and Translational Limitations

Alzheimer’s disease (AD) is one of the leading neurodegenerative disorders affecting over 55 million individuals worldwide, with a limited selection of disease-modifying therapies. The amyloid cascade hypothesis proposes that amyloid-beta (Aβ) peptide accumulation initiates a cascade of synaptic dysfunction, neuroinfla...

R. Menon · 0 citations
Review Open access Oct 2026

Limitations of current neuroprotective therapies in dementia with Lewy bodies.

INTRODUCTION Dementia with Lewy bodies (DLB) is characterized by progressive cognitive, neuropsychiatric, motor, autonomic, and sleep impairment. Pharmacological interventions developed with disease-modifying intent have entered clinical testing, but their biological rationale and adequacy of evaluation remain uncertai...

Deirdre M. O'Shea, Shanell Disla, Alyssa Gosling et al. · 0 citations
Review Open access Sep 2026

Cognition endpoints for Parkinson's disease: A roadmap for developing patient-focused assessment tools to accelerate drug development

Recommendations are made regarding necessary literature reviews, including qualitative data and related conceptual models, disease models including pathophysiology and neuropsychological profile, and clinical outcome assessment (COA) reviews, including content validity, psychometrics, and fitness-for-purpose.

Chris J. Edgar, Kathleen L. Poston, Cheryl D. Coon et al. · 0 citations
Review Open access Aug 2026

NEW THERAPEUTIC OPPORTUNITIES IN ALZHEIMER'S DISEASE: THE ROLE OF ANTI-AMYLOID ANTIBODIES: A COMPREHENSIVE REVIEW

Despite remaining challenges, including safety concerns and the risk of amyloid-related imaging abnormalities, anti-amyloid therapies represent a major advancement in the treatment of Alzheimer's disease and mark a transition toward disease-modifying strategies.

Kacper Jaskulski, Katarzyna Kowalenko, J. Szadkowski et al. · 0 citations
Review Open access Sep 2026

Treatment of Parkinson’s Disease-Related Psychosis

Purpose To provide an updated, clinically oriented overview of therapeutic strategies for Parkinson’s disease-related psychosis (PDP), integrating current evidence on risk factors and available pharmacological and non-pharmacological treatments. Patients and Methods This is a narrative, non-systematic review summarizin...

N. Rocha, Karina Lucia Moreira Sassi, Erin Furr Stimming et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.